Completion of Treatment for Latent Tuberculosis Infection with Monthly Drug Dispensation Directly through the Tuberculosis Clinic

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Dobler, Claudia C ^a,b   Marks, Guy B ^a,b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b LIVERPOOL HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID;

ADOLESCENT; ADULT; AGE; ARTICLE; AUSTRALIA; CHILD; DRUG ERUPTION; DRUG SELF ADMINISTRATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EMPLOYMENT STATUS; FEMALE; GASTROINTESTINAL SYMPTOM; HEALTH CARE PERSONNEL; HEPATITIS; HUMAN; IMMIGRANT; INFANT; LANGUAGE; LATENT TUBERCULOSIS; LETHARGY; MAJOR CLINICAL STUDY; MALE; MOOD DISORDER; NAUSEA; PATIENT COMPLIANCE; PRESCHOOL CHILD; SCHOOL CHILD; SEX DIFFERENCE; SIDE EFFECT; THORAX RADIOGRAPHY; TUBERCULIN TEST; VOMITING;

ADULT; AMBULATORY CARE FACILITIES; ANTITUBERCULAR AGENTS; AUSTRALIA; COHORT STUDIES; FEMALE; HUMANS; ISONIAZID; LATENT TUBERCULOSIS; MALE; PHARMACIES; TREATMENT OUTCOME;

EID: 84868361014     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0048900     Document Type: Article

References (31)

1. Targeted tuberculin testing and treatment of latent tuberculosis infection. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This statement was endorsed by the Council of the Infectious Diseases Society of America. (IDSA), September 1999, and the sections of this statement. Am J Respir Crit Care Med 161: S221-247.
2. Ferebee SH, (1970) Controlled chemoprophylaxis trials in tuberculosis. A general review. Bibl Tuberc 26: 28-106.
3. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. International Union Against Tuberculosis Committee on Prophylaxis. Bull World Health Organ 60: 555-564.
4. Comstock GW, (1999) How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults? Int J Tuberc Lung Dis 3: 847-850.
5. Smieja MJ, Marchetti CA, Cook DJ, Smaill FM (2000) Isoniazid for preventing tuberculosis in non-HIV infected persons. Cochrane Database Syst Rev: CD001363.
6. (2005) Charles P. Felton National Tuberculosis Center. Adherence to Treatment for Latent Tuberculosis Infection: A Manual for Health Care Providers. Link: http://cpmcnet.columbia.edu/dept/harlemtb/Assets/web_docs/Harlem-LTBI%20Adherence6.pdf. Accessed 26th September 2012.
7. Hirsch-Moverman Y, Daftary A, Franks J, Colson PW, (2008) Adherence to treatment for latent tuberculosis infection: systematic review of studies in the US and Canada. Int J Tuberc Lung Dis 12: 1235-1254.
8. Shieh FK, Snyder G, Horsburgh CR, Bernardo J, Murphy C, et al. (2006) Predicting non-completion of treatment for latent tuberculous infection: a prospective survey. Am J Respir Crit Care Med 174: 717-721.
9. Shukla SJ, Warren DK, Woeltje KF, Gruber CA, Fraser VJ, (2002) Factors associated with the treatment of latent tuberculosis infection among health-care workers at a midwestern teaching hospital. Chest 122: 1609-1614.
10. Menzies D, (1999) Interpretation of repeated tuberculin tests. Boosting, conversion, and reversion. Am J Respir Crit Care Med 159: 15-21.
11. (2009) NSW Department of Health. Policy directive: Tuberculin Skin Testing. Link: http://www.health.nsw.gov.au/policies/pd/2009/pdf/PD2009_005.pdf. Accessed 26th September 2012.
12. Trauer JM, Krause VL, (2011) Assessment and management of latent tuberculosis infection in a refugee population in the Northern Territory. Med J Aust 194: 579-582.
13. Sterling TR, Villarino ME, Borisov AS, Shang N, Gordin F, et al. (2011) Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med 365: 2155-2166.
14. Anibarro L, Casas S, Paz-Esquete J, Gonzalez L, Pena A, et al. (2010) Treatment completion in latent tuberculosis infection at specialist tuberculosis units in Spain. Int J Tuberc Lung Dis 14: 701-707.
15. Coly A, Morisky D, (2004) Predicting completion of treatment among foreign-born adolescents treated for latent tuberculosis infection in Los Angeles. Int J Tuberc Lung Dis 8: 703-710.
16. Reichler MR, Reves R, Bur S, Ford J, Thompson V, et al. (2002) Treatment of latent tuberculosis infection in contacts of new tuberculosis cases in the United States. South Med J 95: 414-420.
17. Nyamathi AM, Christiani A, Nahid P, Gregerson P, Leake B, (2006) A randomized controlled trial of two treatment programs for homeless adults with latent tuberculosis infection. Int J Tuberc Lung Dis 10: 775-782.
18. Goswami ND, Gadkowski LB, Piedrahita C, Bissette D, Ahearn MA, et al. (2012) Predictors of latent tuberculosis treatment initiation and completion at a U.S. public health clinic: a prospective cohort study. BMC Public Health 12: 468.
19. Hirsch-Moverman Y, Bethel J, Colson PW, Franks J, El-Sadr W, (2010) Predictors of latent tuberculosis infection treatment completion in the United States: an inner city experience. Int J Tuberc Lung Dis 14: 1104-1111.
20. Page KR, Sifakis F, Montes de Oca R, Cronin WA, Doherty MC, et al. (2006) Improved adherence and less toxicity with rifampin vs isoniazid for treatment of latent tuberculosis: a retrospective study. Arch Intern Med 166: 1863-1870.
21. Menzies D, Dion MJ, Rabinovitch B, Mannix S, Brassard P, et al. (2004) Treatment completion and costs of a randomized trial of rifampin for 4 months versus isoniazid for 9 months. Am J Respir Crit Care Med 170: 445-449.
22. Codecasa LR, Besozzi G, (1998) Acceptance of isoniazid preventive treatment by close contacts of tuberculosis cases: a 692-subject Italian study. Int J Tuberc Lung Dis 2: 208-212.
23. Sebastian MS, Bothamley GH, (2000) Tuberculosis preventive therapy: perspective from a multi-ethnic community. Respir Med 94: 648-653.
24. Watkins RE, Rouse CR, Plant AJ, (2004) Tuberculosis treatment delivery in Bali: a qualitative study of clinic staff perceptions. Int J Tuberc Lung Dis 8: 218-225.
25. Parsyan AE, Saukkonen J, Barry MA, Sharnprapai S, Horsburgh CR Jr, (2007) Predictors of failure to complete treatment for latent tuberculosis infection. J Infect 54: 262-266.
26. Kwara A, Herold JS, Machan JT, Carter EJ, (2008) Factors associated with failure to complete isoniazid treatment for latent tuberculosis infection in Rhode Island. Chest 133: 862-868.
27. Horsburgh CR Jr, Goldberg S, Bethel J, Chen S, Colson PW, et al. (2010) Latent TB infection treatment acceptance and completion in the United States and Canada. Chest 137: 401-409.
28. Trajman A, Long R, Zylberberg D, Dion MJ, Al-Otaibi B, et al. (2010) Factors associated with treatment adherence in a randomised trial of latent tuberculosis infection treatment. Int J Tuberc Lung Dis 14: 551-559.
29. Menzies D, Dion MJ, Francis D, Parisien I, Rocher I, et al. (2005) In closely monitored patients, adherence in the first month predicts completion of therapy for latent tuberculosis infection. Int J Tuberc Lung Dis 9: 1343-1348.
30. Guerra RL, Conde MB, Efron A, Loredo C, Bastos G, et al. (2010) Point-of-care Arkansas method for measuring adherence to treatment with isoniazid. Respir Med 104: 754-757.
31. Hanifa Y, Mngadi K, Lewis J, Fielding K, Churchyard G, et al. (2007) Evaluation of the Arkansas method of urine testing for isoniazid in South Africa. Int J Tuberc Lung Dis 11: 1232-1236.